Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio(Northwestern University), Al B. Benson(Northwestern University), Neal J. Meropol(Flatiron Health (United States)), Paul J. Catalano(Computational Physics (United States)), Edith P. Mitchell(Thomas Jefferson University Hospital), Steven R. Alberts(North Central Cancer Treatment Group), Michael Schwartz(American Society of Clinical Oncology), Peter J. O’Dwyer(University of Pennsylvania)
Cited by 163
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|1.4k